Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
1. A method of treating an autoimmune or inflammatory disease or condition in a subject, comprising administering to the subject a composition comprising an antibody or an antigen binding fragment thereof that binds to human Matrix Metalloprotease 9 (MMP9), wherein the antibody or the antigen binding fragment thereof that binds to human MMP9 comprises a heavy chain variable domain (V H ) comprising three complementarity determining regions (CDRs) comprising the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15 and a light chain variable domain (V L ) comprising three CDRs comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, and wherein the autoimmune or inflammatory disease or condition is rheumatoid arthritis.
2. The method of claim 1 , wherein the heavy chain variable domain (V H ) comprises an amino acid sequence set forth in SEQ ID NO: 7.
3. The method of claim 1 , wherein the light chain variable domain (V L ) comprises an amino acid sequence set forth in SEQ ID NO: 12.
4. The method of claim 1 , wherein the composition inhibits the enzymatic activity of MMP9.
5. The method of claim 4 , wherein the inhibition of the enzymatic activity is non-competitive.
6. The method of claim 1 , wherein the antibody or antigen binding fragment thereof that hinds to human MMP9 is administered at a dose of about 1 mg/kg to about 28 mg/kg.
7. The method of claim 1 , wherein the antibody or antigen binding fragment thereof that binds to human MMP9 is administered at a dose of about 10 ng/kg to about 100 mg/kg body weight per day.
8. The method of claim 7 , wherein the antibody or antigen binding fragment thereof that binds to human MMP9 is administered at a dose of about 1 μg/kg to 50 mg/kg, about 100 μg/kg to 20 mg/kg, about 500 μg/kg to 10 mg/kg, or about 1 mg/kg to 10 mg/kg body weight per day.
9. The method of claim 1 , wherein the composition is administered once every week, once every two weeks, or once every three weeks.
10. The method of claim 1 , wherein the composition is administered intravenously, intra-arterially, intradermally, intramuscularly, subcutaneously, or orally.
11. The method of claim 1 , wherein the composition further comprises one or more therapeutic agents selected from the group consisting of: an anti-inflammatory agent, an immunotherapeutic agent, or a combination thereof.
12. The method of claim 10 , wherein the composition is administered intravenously.
13. The method of claim 10 , wherein the composition is administered subcutaneously.
14. The method of claim 1 , wherein the heavy chain variable domain (V H ) comprises an amino acid sequence set forth in SEQ ID NO: 7, and the light chain variable domain (V L ) comprises an amino acid sequence set forth in SEQ ID NO: 12.
15. The method of claim 14 , wherein the composition further comprises one or more therapeutic agents selected from the group consisting of: an anti-inflammatory agent, an immunotherapeutic agent, or a combination thereof.
16. The method of claim 14 , wherein the subject is human.
17. The method of claim 14 , wherein the composition is administered once every week, once every two weeks, or once every three weeks.
18. The method of claim 14 , wherein the composition is administered intravenously, intra-arterially, intradermally, intramuscularly, subcutaneously, or orally.
19. The method of claim 18 , wherein the composition is administered intravenously.
20. The method of claim 18 , wherein the composition is administered subcutaneously.